Abstract
Background: PPP1R13L gene has been found to be over-expressed in variety of cancers and its expression in
p53 wild-type background is sufficient to promote tumor growth in vivo. However, in the non-transformed
cells it acts as a tumor suppressor which suggests that the role of PPP1R13L is multifaceted.
Methods: We have used siRNA optimized for inhibition of p53, PPP1R13L, BAX and GADD45 alpha expression
and investigated the role of those gene products for PPP1R13L expression and induction in a variety of mouse
and human cells with different p53 status. In addition we have applied Western Blot, Q-PCR and proteasome
inhibition analysis to further ascertain the link between PPP1R13L induction and p53 status.
Results: We show that the pattern and extent of the PPP1R13L expression depend on the presence of active
p53. Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation
after adriamycin and/or etoposide treatments. Treatment of the cells with the proteasome inhibitor MG-132
resulted in the accumulation of both p53 and PPP1R13L proteins.
Conclusions: We have provided evidence that endogenous PPP1R13L acts as a negative regulator of p53
function, presumably by direct binding. p53 accumulation and activity after DNA damage is compromised by
PPP1R13L expression. We suggest that PPP1R13L and p53 form a negative feedback loop which regulates their
amount and activity.
General significance: The profound modulatory effect of the PPP1R13L protein on the ability of p53 to cause
cellular apoptosis has important implications in cancer and presents new therapeutic possibilities.
p53 wild-type background is sufficient to promote tumor growth in vivo. However, in the non-transformed
cells it acts as a tumor suppressor which suggests that the role of PPP1R13L is multifaceted.
Methods: We have used siRNA optimized for inhibition of p53, PPP1R13L, BAX and GADD45 alpha expression
and investigated the role of those gene products for PPP1R13L expression and induction in a variety of mouse
and human cells with different p53 status. In addition we have applied Western Blot, Q-PCR and proteasome
inhibition analysis to further ascertain the link between PPP1R13L induction and p53 status.
Results: We show that the pattern and extent of the PPP1R13L expression depend on the presence of active
p53. Downregulation of p53 target genes BAX and/or GADD45 alpha led to decreased in PPP1R13L activation
after adriamycin and/or etoposide treatments. Treatment of the cells with the proteasome inhibitor MG-132
resulted in the accumulation of both p53 and PPP1R13L proteins.
Conclusions: We have provided evidence that endogenous PPP1R13L acts as a negative regulator of p53
function, presumably by direct binding. p53 accumulation and activity after DNA damage is compromised by
PPP1R13L expression. We suggest that PPP1R13L and p53 form a negative feedback loop which regulates their
amount and activity.
General significance: The profound modulatory effect of the PPP1R13L protein on the ability of p53 to cause
cellular apoptosis has important implications in cancer and presents new therapeutic possibilities.
| Original language | English |
|---|---|
| Journal | Biochimica et Biophysica Acta - General Subjects |
| Volume | 1800 |
| Issue number | 12 |
| Pages (from-to) | 1231-1240 |
| ISSN | 0304-4165 |
| DOIs | |
| Publication status | Published - 2010 |
Keywords
- DNA damage
- p53 tumor suppressor
- PPP1R13L
- Apoptosis
- Proteasome inhibitor
Citation Styles
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver